Table 7.
Response rates by first-line regimen and histologic category, overall.
| Characteristic | Best response according to RECISTa | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | No response/disease progression | |
| First-line regimen, n (%) | ||||
| Doxorubicin (n=330) | 5 (1.5) | 120 (36.4) | 115 (34.9) | 87 (26.4) |
| Doxorubicin + ifosfamideb (n=153) | 14 (9.2) | 71 (46.4) | 40 (26.1) | 28 (18.3) |
| Docetaxel + gemcitabine (n=70) | 3 (4.3) | 35 (50.0) | 18 (25.7) | 14 (20.0) |
| Paclitaxel (n=34) | 5 (14.7) | 9 (26.5) | 6 (17.7) | 13 (38.2) |
| Ifosfamideb (n=33) | 0 | 7 (21.2) | 14 (42.4) | 11 (33.3) |
| All other regimens (n=186) | 18 (9.6) | 71 (38.0) | 54 (28.9) | 43 (23.0) |
|
| ||||
| Histologic category c n (%) | ||||
| Leiomyosarcoma (n=229) | 15 (6.6) | 104 (45.4) | 66 (28.8) | 44 (19.2) |
| Others/NOS (n=183) | 7 (3.8) | 70 (38.3) | 52 (28.4) | 52 (28.4) |
| Fibroblastic/myofibroblastic sarcoma (n=78) | 5 (6.4) | 24 (30.8) | 34 (43.6) | 15 (19.2) |
| Liposarcoma (n=105) | 4 (3.8) | 34 (32.4) | 32 (30.5) | 32 (30.5) |
| Vascular sarcoma (n=79) | 8 (10.1) | 25 (31.7) | 22 (27.9) | 23 (29.1) |
| Rhabdomyosarcoma (n=86) | 5 (5.8) | 41 (47.7) | 22 (25.6) | 18 (20.9) |
| Synovial sarcoma (n=47) | 1 (2.1) | 15 (31.9) | 19 (40.4) | 12 (25.5) |
NOS: not otherwise specified; RECIST: Response Evaluation Criteria in Solid Tumors; aamong patients with known response; bmesna was always coadministered with ifosfamide; cresponse rates are for first-line regimens administered in each histologic category.